Advice
In the absence of a submission from the holder of the marketing authorisation:
eculizumab (Soliris ®) is not recommended for use within NHSScotland.
Indication under review: Treatment of adults with refractory generalised myasthenia gravis who are anti-acetylcholine receptor antibody-positive.
The holder of the marketing authorisation has not made a submission to SMC regarding this product in this indication. As a result we cannot recommend its use within NHSScotland.
Download detailed advice361KB (PDF)
Medicine details
- Medicine name:
- eculizumab (Soliris)
- SMC ID:
- SMC2236
- Indication:
Treatment of adults with refractory generalised myasthenia gravis who are anti-acetylcholine receptor antibody-positive.
- Pharmaceutical company
- Alexion Pharma UK Ltd
- Submission type
- Non submission
- Status
- Not recommended
- Date advice published
- 07 October 2019